Tamoxifen and Secondary Tumours

This publication has 96 references indexed in Scilit:

• Tamoxifen and Tumorigenicity: a Predictable Concern
  JNCI Journal of the National Cancer Institute, 1995
• Should clinicians be concerned about the carcinogenic potential of tamoxifen?
  European Journal Of Cancer, 1994
• Tamoxifen: evidence by ³²P–postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4–hydroxytamoxifen as a proximate metabolite
  Carcinogenesis: Integrative Cancer Research, 1994
• Endometrial lesions in patients undergoing tamoxifen therapy
  International Journal of Gynecology & Obstetrics, 1991
• Transforming growth factor β1 is implicated in the failure of tamoxifen therapy in human breast cancer
  British Journal of Cancer, 1991
• Quantitative predictability of carcinogenicity of the covalent binding index of chemicals to DNA: comparison of the in vivo and in vitro assays.
  Environmental Health Perspectives, 1990
• A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive Tumors
  New England Journal of Medicine, 1989
• Effect of tamoxifen and tamoxifen derivatives on the conversion of estrone-sulfate to estradiol in the R-27 cells, a tamoxifen-resistant line derived from MCF-7 human breast cancer cells
  Journal of Steroid Biochemistry, 1988
• The Stockholm trial on adjuvant tamoxifen in early breast cancer
  Breast Cancer Research and Treatment, 1987
• Tamoxifen in advanced breast cancer
  Cancer Treatment Reviews, 1978